0000000000199453

AUTHOR

Elisabetta F. Buonaguro

showing 2 related works from this author

The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions

2017

Cardio-vascular diseases (CVDs) and CVD-related disorders (including cerebrovascular diseases; CBVDs) are a major public health concern as they represent the leading cause of mortality and morbidity in developed countries. Patients with CVDs and CBVDs co-morbid with mood disorders, especially bipolar disorder (BD) and major depressive disorder (MDD), suffer reduced quality-of-life and significant disability adjusted for years of life and mortality. The relationship between CVDs/CBVDs and mood disorders is likely to be bidirectional. Evidence for shared genetic risk of pathways involved in stress reaction, serotonin or dopamine signalling, circadian rhythms, and energy balance was reported i…

cognitionmedicine.medical_specialtyPsychological interventionphysical activity03 medical and health sciences0302 clinical medicineNeurobiologycardiovascular diseasemental disordersmedicineHumansBipolar disorderPsychiatrybipolar disorderpsychopharmacologyexerciseMood DisordersDepression; bipolar disorder; cardiovascular disease; cognition; comorbidity; exercise; physical activity; psychopharmacology; quality-of-life; strokeDepressionmedicine.diseaseComorbiditystroke030227 psychiatryCerebrovascular DisordersPsychiatry and Mental healthcomorbidityMoodHypomaniaMood disordersquality-of-lifeMajor depressive disordermedicine.symptomPsychologybipolar disorder; cardiovascular disease; cognition; comorbidity; Depression; exercise; physical activity; psychopharmacology; quality-of-life; strokeMania030217 neurology & neurosurgeryClinical psychology
researchProduct

Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews

2017

Introduction. A burgeoning number of systematic reviews considering lurasidone in the treatment of bipolar depression have occurred since its Food and Drug Administration extended approval in 2013. While a paucity of available quantitative evidence still precludes preliminary meta-analysis on the matter, the present quality assessment of systematic review of systematic reviews, nonetheless, aims at highlighting current essential information on the topic. Methods. Both published and unpublished systematic reviews about lurasidone mono- or adjunctive therapy in the treatment of bipolar depression were searched by two independent authors inquiring PubMed/Cochrane/Embase/Scopus from inception u…

Genetics and Molecular Biology (all)Transtorno Bipolarmedicine.medical_specialtyBipolar DisorderImmunology and Microbiology (all)ConcordanceDrug profileAlternative medicineMEDLINElcsh:MedicineReview ArticleBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesLurasidone Hydrochloride0302 clinical medicineImmunology and Microbiology (all); Biochemistry Genetics and Molecular Biology (all)medicineBipolar DepressionHumansPsychiatryDrug ApprovalDepression (differential diagnoses)LurasidoneGeneral Immunology and Microbiologybusiness.industrylcsh:RGeneral Medicine030227 psychiatrySystematic reviewTolerabilityDepressãobusiness030217 neurology & neurosurgerymedicine.drugLurasidone
researchProduct